Clinical Trials Logo
  1. Home
  2. Pseudomonas Aeruginosa
  3. NCT05642767

Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa — Pseudomonas  

Pseudomonas Aeruginosa Clinical Trial

Official title:
Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa

Clinical Trial Summary

Pseudomonas aeruginosa (PA) is a ubiquitous aerobic, non-fermentative Gram-negative rod that is widely associated with nosocomial pneumonia and can lead to severe illness with poor outcomes, particularly in critically ill people due to the ability of some strains to cause lung epithelial injury and spread into the circulation. 2 In the intensive care unit, PA infection is ranked among the top five causes of the bloodstream, pulmonary, surgical site, urinary tract, and soft tissue infections.

Clinical Trial Description

The pathogenesis of PA infections is multifactorial, and it is frequently complicated by the bacteria's intrinsic resistance to some antimicrobial agents such as sulfonamides, tetracyclines, and trimethoprim, as well as its ability to acquire or quickly develop resistance to major classes of antibiotics such as aminoglycosides, quinolones, B-lactams, and polymyxins (Bassetti et al., 2018). The efflux systems, which mediate the expulsion of antibiotics out of the cell shortly after entry, the production of enzymes to inactivate antibiotics, and the decrease in permeability across the cell wall are some mechanisms used by PA to develop antimicrobial resistance (Meletis & Bagkeri, 2013). PA possesses a large number of virulence factors that play a significant role in pathogenesis and the determination of infection severity. These virulence factors act alone or in synergy with each other to cause tissue damage, necrosis, and cell death. Among the virulence factors of PA, the major determinants of virulence are the type III secretion system (T3SS) and quorum sensing (cell-to-cell signaling system). The T3SS is a needle-like complex, also known as the injectisome, that enables a bacterium to deliver different effector proteins such as ExoS, ExoT, ExoU, and ExoY across the membrane into a host cell, altering host cell functions and increasing bacterial survival rates ( Horna G and, Ruiz J, 2021). In this study, we aimed to evaluate the prevalence of antibiotic resistance caused by the presence of Efflux genes and some virulence factors in Pseudomonas aeruginosa from clinical isolates. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05642767
Study type Observational
Source Sohag University
Contact Noha S Shafik, lecturer
Phone 01067261504
Email Nohasaber@med.sohag.edu.eg
Status Recruiting
Phase
Start date December 1, 2022
Completion date May 1, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Not yet recruiting NCT06035055 - Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis Phase 4
Completed NCT00774072 - Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization Phase 2
Completed NCT00515229 - Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo Phase 2
Terminated NCT00333385 - Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Phase 4
Recruiting NCT03638830 - Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Phase 2
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT00633191 - Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis Phase 1/Phase 2
Completed NCT00712166 - Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa Phase 3
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT02696902 - Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects Phase 2
Completed NCT01319253 - A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies N/A
Recruiting NCT05282082 - Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Recruiting NCT04803695 - Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Completed NCT01055847 - Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Phase 2
Completed NCT01745796 - Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)
Recruiting NCT04673175 - Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Recruiting NCT05616221 - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Phase 2